Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method and application of nucleic acid spherical nano particle drug

A nanoparticle and nucleic acid technology, which is applied in the direction of drug combinations, pharmaceutical formulas, medical preparations of non-active ingredients, etc., can solve the problems of low delivery efficiency, achieve the effects of not easy to degrade, good stability, and increase local effective concentration

Active Publication Date: 2019-05-17
SUZHOU WEAST BIOTECHNOLOGY CO LTD
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide nucleic acid spherical nanoparticle drugs for efficient cytoplasmic gene delivery, and solve the problem of low delivery efficiency in existing delivery methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of nucleic acid spherical nano particle drug
  • Preparation method and application of nucleic acid spherical nano particle drug
  • Preparation method and application of nucleic acid spherical nano particle drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation method of DNA NPs-18 nt: Mix 500 nM DNA-18 nt and 45 μM disulfide monomer compound in 20 mM Tris-HCl buffer (pH = 7.5) at 37°C for 15 min. Subsequently, unreacted DNA and disulfide monomer compounds were removed by dialysis in water for 48 h to finally obtain DNA NPs-18 nt. The particle size of the DNA NPs-18nt synthesized in this example is about 50 nm. To optimize the assembly conditions, different concentrations of disulfide monomer compounds were added to Tris-HCl buffer (pH = 7.5) containing 5 μM DNA-18 nt (N / P = 1~15).

[0047] In Example 1, survivin mRNA was used as the target positive-sense RNA, wherein Random DNA, DNA-18 nt and its positive-sense RNA—survivin mRNA sequences are shown in Table 1.

[0048] The sequence list of DNA and sense RNA adopted in the embodiment and comparative example of table 1

[0049]

[0050] Note: The target sequence of the survivin probe is the NO.305-NO.321 base interval of survivin mRNA with a total length of 265...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a preparation method and application of a nucleic acid spherical nano particle drug. The nucleic acid spherical nano particle drug is formed by the self-assembly of a disulfidemonomer compound and a complementary detecting target positive-sense nucleic acid sequence. The nucleic acid spherical nano particle drug has the advantages that the drug can enter cytoplasm through anon-endocytosis approach to be rapidly depolymerized by cell endogenous glutathione (GSH) to promote the decomposition of nano particles and the releasing of nucleic acid to be used for genetic treatment, and the expression of tumor related genes is inhibited.

Description

technical field [0001] The invention belongs to the field of biological gene therapy, in particular to a preparation method and application of nucleic acid spherical nanoparticle medicine. Background technique [0002] Gene therapy has broad application prospects for the treatment of various diseases such as cancer, genetic diseases and viral infections. Currently, many nucleic acid drugs are in clinical trials, and some drugs have been approved in the United States and Europe. Despite great progress, the commercial development of nucleic acid drugs still faces several challenges, such as enzymatic degradation, inefficient cytoplasmic delivery, rapid hepatic clearance, and nonspecific side effects. [0003] Successful gene therapy depends largely on the development of delivery vehicles with high transfection efficiency and low cytotoxicity. Both viral and non-viral vectors can be used to package nucleic acids and facilitate cellular uptake. Viral vectors are widely used f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7088A61K47/54A61P35/00
CPCA61K47/54A61K47/6929A61K31/7088A61P35/00B82Y5/00
Inventor 李娟孙丽芹周洁李婧影杨黄浩
Owner SUZHOU WEAST BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com